Diabetes & Metabolism Journal

Original Article

Therapeutic Target Achievement in Type 2 Diabetic Patients after Hyperglycemia, Hypertension, Dyslipidemia Management: Ah Young Kang, Su Kyung Park, So Young Park, Hye Jeong Lee, Ying Han, Sa Ra Lee, Sung Hwan Suh, Duk Kyu Kim, Mi Kyoung Park; Diabetes Metab J. 2011;35(3):264-272. Published online June 30, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.3.264

10,052 View
35 Download
12 Crossref

Background

Our study group established "3H care" in 2002. The meaning of "3H care" attain and maintain adequate controls over hypertension, hyperlipidemia, and hyperglycemia in type 2 diabetic patients. This study evaluated the achievement of target goals after one year or more of "3H care" by specialists in our diabetic clinic.

Methods

This was a retrospective study of 200 type 2 diabetic patients who received "3H care" for one year or more in our diabetic clinic. We evaluated achievement of target goals for metabolic controls as suggested by the American Diabetes Association.

Results

Overall, 200 type 2 diabetes patients were enrolled, of whom 106 were males (53%) and 94 were females (47%). After one year of "3H care," the mean HbA1c was 7.2±1.5% and the percentage of patients achieving glycemic control (HbA1c <7%) was 51.8%. However only 32.2% of hypertensive patients achieved the recommended target. After one year of "3H care," the percentages of those who achieved the target value for dyslipidemia were 80.0% for total cholesterol, 66.3% for low density lipoprotein cholesterol, 57.9% for triglyceride, and 51.8% for high density lipoprotein cholesterol. The percentage that achieved all three targets level was only 4.4% after one year and 14.8% after two years.

Conclusion

The results of this study demonstrate that only a minor proportion of patients with type 2 diabetes achieved the recommended goals despite the implementation of "3H care." It is our suggestion that better treatment strategies and methods should be used to control hypertension, hyperlipidemia and hyperglycemia.

Citations

Citations to this article as recorded by

Achievement of the ABC goal among Canadians with type 2 diabetes and the influence of physical activity: data from the Canadian Health Measures Survey
Alexis Marcotte-Chénard, René Maréchal, Ahmed Ghachem, Alan Cohen, Eléonor Riesco
Applied Physiology, Nutrition, and Metabolism.2023; 48(9): 657. CrossRef
Poor Adherence to Common Recommendations and Associated Factors among Outpatients with Type 2 Diabetes Mellitus in a Police Hospital of Ethiopia
Tariku Shimels, Melesse Abebaw, Gebremedhin Beedemariam Gebretekle
Journal of Social Health and Diabetes.2021; 9(01): e8. CrossRef
Prevalence and correlation of glycemic control achievement in patients with type 2 diabetes in Iraq: A retrospective analysis of a tertiary care database over a 9-year period
Abbas Ali Mansour, Nassar T.Y. Alibrahim, Haider A. Alidrisi, Ali H. Alhamza, Ammar M. Almomin, Ibrahim Abbood Zaboon, Muayad Baheer Kadhim, Rudha Naser Hussein, Hussein Ali Nwayyir, Adel Gassab Mohammed, Dheyaa K.J. Al-Waeli, Ibrahim Hani Hussein
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(3): 265. CrossRef
Notoginsenoside R1 Ameliorates Diabetic Retinopathy through PINK1-Dependent Activation of Mitophagy
Ping Zhou, Weijie Xie, Xiangbao Meng, Yadong Zhai, Xi Dong, Xuelian Zhang, Guibo Sun, Xiaobo Sun
Cells.2019; 8(3): 213. CrossRef
Association of Self-Reported Dietary and Drug Compliance with Optimal Metabolic Control in Patients with Type 2 Diabetes: Clinic-Based Single-Center Study in a Developing Country
Thilak Priyantha Weerarathna, Miyuru Kavinda Weerarathna, Vidarsha Senadheera, Herath Mudiyanselage Meththananda Herath, Gayani Liyanage
Journal of Nutrition and Metabolism.2018; 2018: 1. CrossRef
Prevalence of primary aldosteronism among patients with type 2 diabetes
Mauro Tancredi, Gudmundur Johannsson, Björn Eliasson, Robert Eggertsen, Ulf Lindblad, Sofia Dahlqvist, Henrik Imberg, Marcus Lind
Clinical Endocrinology.2017; 87(3): 233. CrossRef
GS-E3D, a new pectin lyase-modified red ginseng extract, inhibited diabetes-related renal dysfunction in streptozotocin-induced diabetic rats
Chan-Sik Kim, Kyuhyung Jo, Jin Sook Kim, Mi-Kyung Pyo, Junghyun Kim
BMC Complementary and Alternative Medicine.2017;[Epub] CrossRef
Ursodeoxycholic acid and 4-phenylbutyrate prevent endoplasmic reticulum stress-induced podocyte apoptosis in diabetic nephropathy
Ai-Li Cao, Li Wang, Xia Chen, Yun-Man Wang, Heng-Jiang Guo, Shuang Chu, Cheng Liu, Xue-Mei Zhang, Wen Peng
Laboratory Investigation.2016; 96(6): 610. CrossRef
Ursodeoxycholic Acid Ameliorated Diabetic Nephropathy by Attenuating Hyperglycemia-Mediated Oxidative Stress
Aili Cao, Li Wang, Xia Chen, Hengjiang Guo, Shuang Chu, Xuemei Zhang, Wen Peng
Biological & Pharmaceutical Bulletin.2016; 39(8): 1300. CrossRef
Withania coagulansFruit Extract Reduces Oxidative Stress and Inflammation in Kidneys of Streptozotocin-Induced Diabetic Rats
Shreesh Ojha, Juma Alkaabi, Naheed Amir, Azimullah Sheikh, Ahmad Agil, Mohamed Abdelmonem Fahim, Abdu Adem
Oxidative Medicine and Cellular Longevity.2014; 2014: 1. CrossRef
Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: results from INSPIRE ME IAA
J. Smith, J.‐A. Nazare, A.‐L. Borel, P. Aschner, P. J. Barter, L. Van Gaal, Y. Matsuzawa, T. Kadowaki, R. Ross, C. Brulle‐Wohlhueter, N. Alméras, S. M. Haffner, B. Balkau, J.‐P. Després
Diabetes, Obesity and Metabolism.2013; 15(7): 629. CrossRef
Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?
Pitchai Balakumar, Supriya Kadian, Nanjaian Mahadevan
Pharmacological Research.2012; 65(4): 430. CrossRef

Response

Response: A Retrospective Study on the Efficacy of a Ten-Milligram Dosage of Atorvastatin for Treatment of Hypercholesterolemia in Type 2 Diabetes Mellitus Patients (Korean Diabetes J 2010;34:359-67): Dong Kyun Kim, Sa Rah Lee, Min Sik Kim, Suk Hyang Bae, Jin Yeon Hwang, Jung-Min Kim, Sung Hwan Suh, Hye-Jeong Lee, Mi Kyoung Park, Duk Kyu Kim; Diabetes Metab J. 2011;35(1):88-89. Published online February 28, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.1.88

3,820 View
22 Download

PDF PubReader

Original Article

A Retrospective Study on the Efficacy of a Ten-Milligram Dosage of Atorvastatin for Treatment of Hypercholesterolemia in Type 2 Diabetes Mellitus Patients: Dong Kyun Kim, Sa Rah Lee, Min Sik Kim, Suk Hyang Bae, Jin Yeon Hwang, Jung-Min Kim, Sung Hwan Suh, Hye-Jeong Lee, Mi Kyoung Park, Duk Kyu Kim; Korean Diabetes J. 2010;34(6):359-367. Published online December 31, 2010; DOI: https://doi.org/10.4093/kdj.2010.34.6.359

5,045 View
25 Download
3 Crossref

Abstract PDF PubReader

Background

There have been few clinical studies on 10 mg atorvastatin as a starting dosage for treatment of hypercholesterolemia in type 2 diabetes mellitus (T2DM) patients. This retrospective study aims to evaluate the efficacy of 10 mg dosage of atorvastatin in clinical setting.

Methods

One hundred five enrolled patients with high levels of low density lipoprotein cholesterol (LDL-C, > 100 mg/dL) took 10 mg atorvastatin. After 6 months, they were divided into 'Responder group' (LDL-C < 100 mg/dL) and 'Non-responder group' (LDL-C ≥ 100 mg/dL), and the response rate was calculated. Thereafter, we subdivided the 'Responder group' into Maintenance (10 mg), Reduced dosage (5 mg), and Discontinuance group (0 mg). The 'Non-Responder group' was subdivided into Maintenance (10 mg) and Double dosage group (20 mg). After consecutive 6 months, the response rates of each 10 mg Maintenance groups were compared to those of the other groups, respectively.

Results

Following the first 6 months, the response rate of 10 mg fixed dosage was 74.3%. In the 'Responder group', response rates of 10 mg, 5 mg and Discontinuance groups following 6 months were 52.6%, 53.1%, and 12.5%, respectively. In the 'Non-responder group', response rates of 10 mg and 20 mg groups were 28.6% and 50.0%. Baseline LDL-C levels and body mass index (BMI) of 'Responder group' were significantly lower than those of 'Non-responder group' (P = 0.004, respectively).

Conclusion

Hypercholesterolemia treatment with 10 mg, fixed dosage of atorvastatin was effective in three quarters of the subjects during the first 6-month treatment; however, a significant number of patients with high LDL-C levels and/or BMI require higher starting and maintenance dosage.

Citations

Citations to this article as recorded by

Preparation and Release Behavior of Atorvastatin Calcuim - Encapsulated Polyoxalate Microspheres
Cheon Jung Lee, Su Young Kim, Hyun Gu Lee, Jaewon Yang, Jin Young Park, Se Rom Cha, Dong-Kwon Lim, Dongwon Lee, Gilson Khang
Polymer Korea.2014; 38(5): 656. CrossRef
A Retrospective Study on the Efficacy of a Ten-Milligram Dosage of Atorvastatin for Treatment of Hypercholesterolemia in Type 2 Diabetes Mellitus Patients (Korean Diabetes J 2010;34:359-67)
Eun-Jung Rhee
Diabetes & Metabolism Journal.2011; 35(1): 86. CrossRef
Response: A Retrospective Study on the Efficacy of a Ten-Milligram Dosage of Atorvastatin for Treatment of Hypercholesterolemia in Type 2 Diabetes Mellitus Patients (Korean Diabetes J 2010;34:359-67)
Dong Kyun Kim, Sa Rah Lee, Min Sik Kim, Suk Hyang Bae, Jin Yeon Hwang, Jung-Min Kim, Sung Hwan Suh, Hye-Jeong Lee, Mi Kyoung Park, Duk Kyu Kim
Diabetes & Metabolism Journal.2011; 35(1): 88. CrossRef

First
Prev
Page of 1
Next
Last

Search